NCT02939599View on ClinicalTrials.gov

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

November 6, 2018

Study Completion Date

November 6, 2018

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

QCC374

0.015mg and 0.06mg

Trial Locations (4)

15261

Novartis Investigative Site, Pittsburgh

69120

Novartis Investigative Site, Heidelberg

01307

Novartis Investigative Site, Dresden

CB23 3RE

Novartis Investigative Site, Cambridge

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY